Nectar Lifesciences
- Market cap
- ₹ 200 Cr.
- P/E
- 17.6x
- P/B
- 0.36x
- 52-week range
- 9.3 – 22.4
- ROE
- −7%
- ROCE
- −5%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Nectar Lifesciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.6 against a typical 34.3: cheaper than most peers (1st = cheapest).47th of 220
- Sales growth−100% against a typical +15.6% from a year earlier.192nd of 197
- Share price, 3 months+1.1% against a typical −0.5%.92nd of 200
- Size₹ 199.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).118th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated B- by Brickwork- CARE lowered its rating on 2 Mar 2026.
- Brickwork expects things to get worse (negative outlook).
- The company stopped sharing information with CARE.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE B+ (Rating Watch with Negative Implications); ISSUER NOT COOPERATING* | — | 2 Mar 2026 |
| Brickwork | BWR B-/BWR A4 | Negative | 16 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 2 Mar 2026 | ▼ Downgrade | CARE B+ (Rating Watch with Negative Implications) | — | CARE | ₹ 930 Cr. | |
| 16 Jan 2026 | Reaffirmed | BWR B-/BWR A4 | — | Brickwork | ₹ 1,215.91 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 30 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 23 Jan 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 3 Dec 2025 | Buyback/Other business matters | To consider buyback for equity shares and other business matters |
| 14 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 14 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating Profit | 27 | 42 | 48 | 40 | −1 | 0 | 0 | −1 | 1 | −2 | −57 | −27 |
| OPM % | 7% | 9% | 11% | 11% | −10% | −500% | −500% | −16% | 77% | — | −4,437% | −6,198% |
| Other Income | 11 | 0 | 1 | 1 | 7 | 8 | −130 | −62 | −176 | 35 | −24 | 3 |
| Interest | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 2 | 11 | 5 | 5 | 8 | −130 | −64 | −176 | 3 | −88 | −24 |
| Tax % | 38% | 36% | 95% | 40% | −2% | 2% | 0% | −1% | 0% | −339% | −22% | −37% |
| Net Profit | 1 | 2 | 1 | 3 | 6 | 8 | −130 | −63 | −176 | 14 | −68 | −15 |
| EPS in Rs | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | −5.8 | −2.82 | −7.85 | 0.64 | −3.5 | −0.79 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −49%
- 5 Years
- −74%
- 3 Years
- −89%
- TTM
- −78%
- 10 Years
- —
- 5 Years
- −4%
- 3 Years
- 4%
- TTM
- −9,161%
- 10 Years
- −11%
- 5 Years
- −19%
- 3 Years
- −26%
- TTM
- —
- 10 Years
- −1%
- 5 Years
- −4%
- 3 Years
- −6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Nectar Lifesciences | ₹ 10.33 | ₹ 200 Cr. | 17.6x | 0.4x | −7% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sanjiv Goyal
- Executive Chairman of the Board, Managing Director
- Amit Chadah
- Chief Executive Officer
- Sushil Kapoor
- Additional Director( Whole-Time Director), Director (Finance)
- Sanjaymohan Singh Rawat
- Compliance Officer, Company Secretary
- Surulichamy Senthilkumar
- Whole-Time Director - R&D
Prices are delayed and for information only. Nothing on this page is investment advice.